Ferozsons secures Gilead license for once-early HIV prevention drug
Ferozsons Laboratories Limited (PSX: FEROZ) has entered into a royalty-free voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP).
September 17, 2026 (MLN): Ferozsons Laboratories Limited (PSX: FEROZ) has entered into a royalty-free voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreement, expanded from the existing twice-yearly lenacapavir access strategy, covers 120 primarily low- and lower-middle-income, high-incidence countries and wil...